Phase Ib dose escalation study of novel immunogenic cell death (ICD) inducer PT-112 plus PD-L1 inhibitor avelumab in solid tumours

被引：4

作者：

Karp, D. D. ^{[1
]}

Dronca, R. S. ^{[2
]}

Camidge, R. ^{[3
]}

Costello, B. A. ^{[4
]}

Mansfield, A. S. ^{[5
]}

Ames, T. D. ^{[6
]}

Jimeno, J. M. ^{[7
]}

Bryce, A. H. ^{[8
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut Dept, Houston, TX 77030 USA

[2] Mayo Clin, Ctr Canc, Dept Internal Med, Div Hematol Oncol, Jacksonville, FL 32224 USA

[3] Univ Colorado, Canc Ctr Anschutz Canc Pavil, Med Oncol, Aurora, CO USA

[4] Mayo Clin, Ctr Canc, Dept Oncol, Div Med Oncol, Rochester, MN USA

[5] Mayo Clin, Div Med Oncol, Dept Oncol, Rochester, MN USA

[6] Phosplatin Therapeut LLC, R&D, New York, NY USA

[7] Phosplatin Therapeut LLC, Clin Dev, New York, NY USA

[8] Mayo Clin, Ctr Canc, Dept Internal Med, Div Hematol Oncol, Phoenix, AZ USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1146

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1026MO

引用

页码：S708 / S708

页数：1

共 50 条

[21] A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma
Lin, Tongyu
Liu, Bin
Pu, Xingxiang
Wu, Lin
Du, Xiaobo
Mo, Ning
Song, Zhengbo
Zhou, Liwei
Duan, Xianlin
Zhu, Yanan
Kang, Xiaoyan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[22] Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
Kotecki, N.
Champiat, S.
Delord, J-P.
Vinceneux, A.
Jungels, C.
Marabelle, A.
Korakis, I.
Wojciekowski, S.
Block, E.
Clarke, N.
Fromond, C.
Poirier, N.
Costantini, D.
Vasseur, B.
Cassier, P. A.
ANNALS OF ONCOLOGY, 2021, 32 : S841 - S842
[23] Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
Takahiro Ebata
Toshio Shimizu
Yutaka Fujiwara
Kenji Tamura
Shunsuke Kondo
Satoru Iwasa
Kan Yonemori
Akihiko Shimomura
Shigehisa Kitano
Takafumi Koyama
Natsuko Sato
Kiyohiko Nakai
Michiyasu Inatani
Noboru Yamamoto
Investigational New Drugs, 2020, 38 : 468 - 477
[24] Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
Ebata, Takahiro
Shimizu, Toshio
Fujiwara, Yutaka
Tamura, Kenji
Kondo, Shunsuke
Iwasa, Satoru
Yonemori, Kan
Shimomura, Akihiko
Kitano, Shigehisa
Koyama, Takafumi
Sato, Natsuko
Nakai, Kiyohiko
Inatani, Michiyasu
Yamamoto, Noboru
INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 468 - 477
[25] Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naive advanced solid tumors
Carneiro, Benedito A.
Safran, Howard
Beck, J. Thaddeus Thaddeus
Hamid, Omid
Spira, Alexander I.
Savvides, Panos
Gutierrez, Martin
Zhao, Yujie
Abbruzzese, James L.
Ward, Jeffrey P.
Weroha, Saravut John
Harris, Loleta D.
Kent, Sean
Pierceall, William
Skoura, Athanasia
Zheng, Jenny
Kern, Kenneth Alan
Thomas, Jacob Stephen
Santana-Davila, Rafael
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[26] Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
Lee, C-H.
Shah, A. Y.
Makker, V.
Taylor, M. H.
Shaffer, D.
Hsieh, J. J.
Cohn, A. L.
DiSimone, C.
Pinto Marin, A.
Rasco, D. W.
Ribe, S. G.
Richards, D. A.
Stepan, D. E.
Dutcus, C. E.
Wu, J.
Schmidt, E. V.
Perini, R. F.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2019, 30 : 483 - +
[27] DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: Phase 1/2 Study of the ATR inhibitor (ATRi) berzosertib and PD-L1 inhibitor avelumab in patients (pts) with advanced solid tumors with DDR molecular alterations
Ngoi, N.
Pilie, P. G.
Piha-Paul, S. A.
Dumbrava, E. E.
Fu, S.
Hong, D. S.
Karp, D. D.
Naing, A.
Pant, S.
Ahnert, J. Rodon
Subbiah, V.
Tsimberidou, A. M.
Salguero, C.
Brown, C. V.
Hoadley, W. E.
Johnson, A.
Yuan, Y.
Westin, S. N.
Meric-Bernstam, F.
Yap, T. A.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S10 - S10
[28] A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
Melisi, Davide
Hollebecque, Antoine
Oh, Do-Youn
Calvo, Emiliano
Varghese, Anna M.
Borazanci, Erkut Hasan
Mercade, Teresa Macarulla
Simionato, Francesca
Park, Joon Oh
Bendell, Johanna C.
Faivre, Sandrine J.
Zhao, Yumin
Gueorguieva, Ivelina
Man, Michael
Estrem, Shawn
Benhadji, Karim Adnane
Lanasa, Mark
Guba, Susan C.
Garcia-Carbonero, Rocio
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[29] First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
Cooper, A.
Andelkovic, V.
Wilkinson, K.
Ganju, V.
Lundy, J.
Hong, M.
Airey, S.
Meng, L. L.
Shen, B.
Li, H.
Yao, L.
Zhang, M.
Coward, J.
ANNALS OF ONCOLOGY, 2023, 34 : S487 - S487
[30] Phase 2 study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
Lee, Chung-Han
Shah, Amishi Y.
Makker, Vicky
Taylor, Matthew
Shaffer, David
Hseih, James J.
Cohn, Allen L.
Di Simone, Chris
Marin, Alvaro Pinto
Rasco, Drew
Gunnestad-Ribe, Sara
Richards, Donald A.
Stepan, Daniel E.
Dutcus, Corina E.
Wu, Jane
Schmidt, Emmett V.
Perini, Rodolfo
Young, Louise
Motzer, Robert
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 101 - 102

← 1 2 3 4 5 →